EIDD-1931 for FIP Treatment | Oral Antiviral for Cats

EIDD-1931 | Advanced Antiviral Therapy for Feline Infectious Peritonitis (FIP)

Less than 2.5 kg

€49,00

EIDD-1931 | Advanced Antiviral Therapy for Feline Infectious Peritonitis (FIP)

€49,00

CureFIP™ delivers pure EIDD-1931 — the active antiviral metabolite of molnupiravir — in a formulation designed exclusively for feline physiology. By using EIDD-1931 directly rather than modifying human molnupiravir 200mg, CureFIP™ EIDD-1931 capsules provides a more precise, consistent, and veterinary-appropriate approach to FIP treatment.

Antiviral Potency

EIDD-1931 exhibits up to 4.4× greater in-vitro antiviral potency compared to molnupiravir (EIDD-2801)
EIDD-1931 demonstrates 7.3× higher potency than GS-441524 under similar test conditions
Each 15 mg capsule is equivalent in activity to approximately 66 mg of molnupiravir

Mechanism of Action

EIDD-1931 inhibits the RNA-dependent RNA polymerase (RdRp) of feline infectious peritonitis virus (FIPV). By mimicking natural nucleosides, it is incorporated into viral RNA during replication, introducing errors that prevent the virus from producing viable copies of itself. This mechanism is effective against both serotype I and serotype II FIPV strains.

Clinical Evidence

A prospective clinical trial involving 62 cats with FIP treated with molnupiravir — which is metabolized to EIDD-1931 — reported a treatment success rate of 77%, with an 11% relapse rate; all cats that relapsed responded to an increased dose.

A dedicated EIDD-1931 study administered orally twice daily at a median dose of 18.75 mg/kg demonstrated complete response in 9 cats across both effusive and non-effusive FIP presentations.

Pharmacokinetic studies confirm that after oral administration, NHC serum concentrations reach levels at least four times the reported in vitro IC50 for feline coronavirus strains throughout the dosing interval, supporting the twice-daily protocol.

Indications

EIDD-1931 is indicated for:

First-line treatment of effusive (wet) and non-effusive (dry) FIP where GS-441524 is unavailable or cost-prohibitive
Rescue therapy in cats that have relapsed or failed to respond to GS-441524-based treatment
Neurological and ocular FIP at adjusted higher dosing, where CNS penetration is required

Monitoring Requirements

Due to EIDD-1931's narrower therapeutic window compared to GS-441524, clinical monitoring is more important. Recommended schedule:

Complete blood count (CBC) at baseline, week 4, and month 2 — watch for neutropenia
ALT and liver enzymes at baseline and weeks 4 and 8 — transient ALT elevations reported in some cats
A/G ratio and albumin — key indicators of treatment response
AGP (alpha-1-acid glycoprotein) where available — sensitive early marker of disease activity

Safety and Adverse Effects

Reported adverse effects in clinical studies include neutropenia, transient or persistent ALT elevation, hyporexia, and broken whiskers. These are generally manageable with dose adjustment or supportive care.

Important contraindications:

Do not use in pregnant or breeding cats. EIDD-1931 carries teratogenic risk and should not be administered to queens intended for breeding during or within 90 days of treatment.
Use with caution in cats with pre-existing hepatic insufficiency.
Concerns regarding host mutagenicity mean that GS-441524 should be preferred where both options are available and accessible.

Position Within FIP Treatment Protocols

Current veterinary guidance positions EIDD-1931 as a sound alternative option where GS-441524 is financially prohibitive or unavailable, and as a second-line antiviral for cats that fail to respond to GS-441524-based therapy. Emerging evidence also supports its use as a primary treatment in effusive FIP with results comparable to GS-441524.

This information is intended for educational purposes and should be used in conjunction with veterinary clinical assessment. Treatment protocols should be supervised by a licensed veterinarian familiar with FIP management.

Administer 1 capsule per 2.5 kg of body weight, every 12 hours, preferably on an empty stomach.
If vomiting occurs within 30 minutes of administration, give an additional dosage.

Example: a cat weighting 4 kg requires 2 capsules of EIDD0-1931 every 12 hours.

Doses should be adjusted based on weight gain, clinical response, and bloodwork at weeks 4 and 8. If relapse occurs, dose escalation is required to achieve complete recovery.

Shelf life: 2 year from the date of manufacture.

Storage: Store capsules at a dry and cool place, away from sun light, ideally in refrigerators at temperatures below 8°C (46°F).

Shipping Time:
1~3 days, Asia (including Middle East)
1~3 days, Oceania
1~2 days, Europe & UK
1~2 days, North America
4~5 days, Latin America

Shipping Condition:
Shipped under ambient temperature. This product is chemically stable at ambient temperature for ordinary shipping and time spent in Customs.

Packaging: Individually packaged in recyclable paper box.

What is EIDD-1931 and how is it different from GS-441524?
Both are oral antivirals that treat FIP by stopping the feline coronavirus from replicating. GS-441524 is currently the most widely used first-line treatment. EIDD-1931 is the active form of molnupiravir and works through a different mechanism — it causes the virus to make fatal copying errors during replication. It is particularly valuable when GS-441524 is unavailable, unaffordable, or when a cat has not responded to GS-441524 treatment.

Can EIDD-1931 treat all forms of FIP?
Yes. EIDD-1931 has been used successfully for effusive (wet) FIP, non-effusive (dry) FIP, and cases with neurological or ocular involvement. Neurological and ocular cases require higher doses and closer monitoring, but response has been documented across all FIP presentations.

Is EIDD-1931 a new, unproven drug?
No. EIDD-1931 is the active metabolite of molnupiravir, which was authorized for human use against SARS-CoV-2. Its antiviral mechanism is well-studied. Clinical trials in cats have confirmed efficacy against FIP, and it has been used successfully in hundreds of cats globally, including as a rescue treatment when other antivirals have failed.

How often should my cat be monitored during treatment?
A complete blood panel is recommended approximately every 30 days alongside regular veterinary evaluation to assess clinical response and determine any dose adjustments.

Goes Well With